Omnispirant Limited

OmniSpirant is an Ireland-based early-stage therapeutics company developing a novel platform technology based on inhaled stem cell exosomes (OmniSomes) for treating respiratory diseases and cancer. The company's proprietary OmniSome technology combines regenerative medicine and gene therapy, leveraging naturally occurring extracellular vesicles to achieve 30–40x more efficient gene transfer than synthetic lipid nanoparticles. OmniSpirant has partnered with Aerogen Limited to optimize inhaled delivery formulations and demonstrated in vivo gene transfer in small animal models, targeting rare respiratory conditions including cystic fibrosis.